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Abstract
Background: Environmental conditions in early life can induce permanent physiological changes, sometimes
increasing the risk of chronic diseases during adulthood. Neural and peripheral circuits controlling energy balance
may be modulated during such a critical period. Since type 1 cannabinoid receptors (CB1R) have recently emerged
as targets for modulating energy balance, their premature chronic activation during early life may result in long-
term metabolic consequences associated to overweight/obesity. Endogenous activation of CB1R mainly occurs after
binding to the endocannabinoid Anandamide (AEA).
Objective: To evaluate long-term effects of AEA treatment during lactation on body weight, epididymal fat
accumulation and related metabolic parameters during adulthood.
Design: Male mice pups were orally treated with a solution of AEA (20 μg/g body weight in soy oil) or vehicle
during the whole lactation period. After weaning, food intake and body weight were recorded every 10 days. Adult
animals were subjected to glucose and insulin tolerance tests. Subsequently, animals were sacrificed and
epididymal fat pads were extracted. Circulating levels of plasma insulin, leptin, non-sterified fatty acids (NEFA),
triglyceride and cholesterol were also evaluated.
Results: AEA-treated mice during lactation showed a significant increase in accumulated food intake, body weight
and epididymal fat during adulthood when compared to control mice. When evaluating CB1R protein expression in
epididymal fat, the AEA-treated group showed a 150 % increase in expression compared to the control mice. This
group also displayed significantly higher levels of circulating glucose, insulin, leptin, triglycerides, cholesterol and
NEFA. Moreover, a marked state of insulin resistance was an important finding in the AEA-treated group.
Conclusion: This study showed that overweight, accumulation of visceral fat and associated metabolic
disturbances, such as a higher lipid profile and insulin resistance, can be programmed by a treatment with the
endocannabinoid AEA during lactation in adult mice.
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Background
The increased body of research referring to early life
events with long-term consequences, arose from earlier
epidemiological studies linking environmental conditions
during infancy to a higher risk of disease and mortality
in adulthood [1,2]. This situation is a consequence of
permanent changes in physiology and/or structure in
response to environmental conditions, due to the devel-
opmental plasticity of living organisms.
Overweight/obesity is a physiopathological condition
characterized by an imbalance between energy intake
and energy expenditure, which may have its origin in
early stages of life. This energy balance is controlled by
complex central and peripheral systems where the endo-
cannabinoid system has been recently recognized as a
critical participant involved in modulating energy
homeostasis, with a role in obesity development [3].
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The endocannabinoid system is mainly composed by
type 1 and 2 cannabinoid receptors (CB1R, CB2R), their en-
dogenous ligands, named endocannabinoids, as well as the
enzymes responsible of their synthesis and hydrolysis. The
two most studied endocannabinoids, arachidonoylethano-
lamide (anandamide; AEA) and 2-arachidonoylglycerol (2-
AG), are synthesized from membrane phospholipids and
are able to activate different pathways depending on a spe-
cific target receptor. Type-1 cannabinoid receptors
expressed in the central nervous system and in several per-
ipheral tissues including liver, skeletal muscle and adipose
tissue, are mainly activated by AEA [4-6]. The CB2R, which
is mainly activated by 2-AG, is expressed in immune and
hematopoietic cells. However, recent studies have reported
the presence of CB2R in some areas of the central nervous
system and in peripheral tissues such as the liver and pan-
creas [7-9].
Type 1 receptors are involved in the control of food in-
take and energy homeostasis [10]. Thus, activation of
CB1R in the hypothalamus increases appetite [11-13],
while its activation in peripheral tissues promotes energy
storage by food intake-independent mechanisms, stimulat-
ing lipid accumulation in adipocytes [14], and de novo
lipogenesis in the liver [5]. Therefore, hyperactivation of
the endocannabinoid system has been proposed to be im-
portant in promoting overweight/obesity and its metabolic
consequences [15-17]. Moreover, blocking endocannabi-
noid action with a CB1R antagonist such as Rimonabant
or AM-251, improves most features of the metabolic syn-
drome. This suggests that increased endocannabinoid tone
may be its unifying pathogenic cause [18].
Higher endocannabinoid levels during lactation could
be originated from maternal feeding or in response to
both acute and repetitive stress [19]. Anandamide and 2-
AG are synthesized from phospholipids containing ara-
chidonic acid (AA), which together with linoleic acid be-
long to the n-6 family of essential fatty acids. Since AA
present in tissues is obtained from the diet, it is expected
that a high intake of n-6 polyunsaturated fatty acids
could lead to elevated endocannabinoid levels in differ-
ent tissues. In the mammary gland, this condition may
result in a higher content of AEA in maternal milk [20],
which in turn should increase availability of this endo-
cannabinoid for lactating pups, with unknown conse-
quences during adult life. Taking the above mentioned
into account, the aim of this study was to evaluate
whether an excess of AEA during lactation could induce
overweight/obesity in adult mice together with a dis-
rupted metabolic profile.
Materials and methods
All procedures performed in this study were approved by
the Bioethics´ Committee for Animal Experimentation of
the Institute of Nutrition and Food Technology, University
of Chile. Santiago, Chile.
Animals
Synchronously pregnant female CD-1 mice were kept in
the animal house under normal conditions of humidity
and temperature (22-24 °C), on a 12:12 h light–dark
cycle. Animals had free access to purified tap water and
food. A normal diet of 4 Kcal/g, equivalent to 2.8 assimi-
lated Kcal/g (Champion Co, Santiago, Chile), was used
during the entire study [21].
From day 16, pregnant female mice were daily exam-
ined at 9:00 and 19:00 h for the presence of pups.
Twelve to 16 h after pup detection, 6-8 litters of homo-
geneous size (12-14 pups) were put together and males
separated from females. Afterwards, six male pups that
exhibited homogeneous weights were randomly selected
and assigned to a substitute mother for random cross
lactation. Animals were then assigned to one of the fol-
lowing groups:
1) Control mice: during the entire lactation (21 d), pups
were removed daily from the home cage, weighed, and 1
μl/g of body weight of soy oil was orally given.
2) AEA-treated mice: during the entire lactation (21 d),
pups were removed daily from the home cage, weighed,
and 20 μg/g body weight of AEA (Sigma-Aldrich Co, St
Luis, MO, USA) in soy oil (1 μl/g body weight) was orally
given.
At 21 days of age, animals were separated from their
mothers, and groups of three animals were placed in
new cages until 150 days of age. During this period, body
weight, food intake, basal metabolic rate, glucose toler-
ance and insulin sensitivity were evaluated. Adult mice
were then sacrificed according to the guidelines for ro-
dent euthanasia provided by the American Medical Vet-
erinary Association [22]. After sacrifice, the whole
epididimal fat pads were extracted from the abdominal
area and weighed. In addition, blood samples were
obtained from the abdominal aorta to evaluate circulat-
ing levels of several metabolic markers as further
described.
Body weight and food intake
Body weight and food intake were recorded every
10 days. The amount of accumulated food intake per
cage (containing three mice) was calculated by subtract-
ing the lost food inside the cage due to spilling from day
21 to 150.
Basal metabolic rate
Measurements of basal metabolic rate were done in
post-absorptive (four hour fasted) and resting 150 day
old mice during the inactive phase and within the
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thermoneutral zone (30 ± 0.5 °C), using standard flow-
through respirometry methods [23].
Western blot of CB1R in epididymal fat
For western blotting procedures, epididymal fat from
AEA-treated and control animals was homogenized
(Heidolph homogenizer DIAX 600) in 500 μl of RIPA
buffer (25 mM Tris–HCl pH7.6, 150 mM NaCl, 1 % so-
dium deoxycholate, 0.1 % SDS) in the presence of prote-
ase inhibitor cocktail (Sigma-Aldrich, catalog number
P2714). The protein was separated in a 10 % SDS-
polyacrylamide gel (Mini protean III System; BIO-RAD)
and subsequently transferred to a PVDF membrane dur-
ing the overnight at 4 °C. A polyclonal antibody for
CB1R was used as the primary antibody (Cayman Chem-
ical, CA, USA) and an enzyme-conjugated anti-rabbit
antibody was used as the secondary antibody (Bio-Rad,
CA, USA). CB1R was visualized by chemiluminiscence
(Western lightning Plus-ECL, enhanced chemilumines-
cence substrate; Perkin Elmer). The obtained protein
bands were normalized against β-actin expression and
quantified using Gel-Pro Analyzer 3.1 programme.
Glucose and insulin tolerance tests
Initially, mice were fasted for 6 h and subsequently
injected with a glucose solution (1.5 mg/g body weight
intraperitoneal). Tail blood was collected immediately
before glucose injection and after 15, 30, 60, 90, and
120 min to evaluate blood glucose levels. Intraperitoneal
insulin tolerance tests (ITT) were performed on 6 h
fasted mice injected with 0.75 U/kg insulin (Eli Lilly)
and tail blood glucose levels were measured (basal, and
15, 30, 45 and 60 min after injection). Blood glucose
levels were determined with an Accu-Check Performa
glucometer (Roche Diagnostics, Mannheim, Germany).
The incremental area under the curve (IAUC) between 0
and 120 min for the glucose tolerance test (GTT), and
the decremental area under de curve (DAUC) between 0
and 60 min for ITT, were determined using the trapez-
oidal method [24].
Plasma glucose, lipids, and hormonal levels
Plasma levels of glucose, triglycerides, and cholesterol
were assessed in triplicate using a commercial enzymatic
kit (DIALAB, Neudorf, Austria). Plasma leptin levels
were assessed in duplicate using a commercial colori-
metric sandwich ELISA Kit (R&D System, Minneapolis,
MN). A commercial ELISA kit was also used to measure
plasma insulin concentration from duplicate samples
(Linco Research, St Charles, MO). Nonesterified fatty
acids (NEFA) concentration in plasma samples were
measured using a HR Series NEFA-HR(2) Kit (Wako
Chemicals USA, Richmond, VA).
Statistical analysis
Data were expressed as mean± SEM. Shapiro-Wilk´s
and Levene tests were previously done to evaluate nor-
mal distribution of data and variance homogeneity. The
Mann-Withney U Test or 1-way ANOVA statistical ana-
lyses were performed, when appropriate. Statistical sig-
nificance was set at P≤0.05. All analyses were conducted
using Stata 10.1 statistical package [25].
Results
Body weight, epididymal Fat and adiposity index
Body weight gain through lactation in both groups of mice
is shown in Figure 1a. At the end of lactation (day 21)
there were no significant differences in body weight be-
tween the control and AEA-treated mice. Time course
body weight from days 30 to 150 showed that AEA-
treated mice had higher body weight, although significant
differences to control mice were obtained from day 120
(Figure 1b). This difference was maintained until day 150,
where this group reached a body weight 15 % higher than
the control mice (55.73 ± 1.3 g vs 48.73± 1.08 g; n= 12; P
< 0.01). In addition to the increased body weight found in
AEA-treated mice, these animals also had a marked in-
crease in epididymal fat content (Figure 2a) when com-
pared to control mice (1.94 ± 0.15 g vs 1.15± 0.15 g;
n=12; P< 0.05). This fact accounts for the higher epididy-
mal adiposity index obtained in AEA-treated mice, which
is determined as the percentage of the total amount of epi-
didymal fat relative to body weight (Figure 2b).
Food intake
The accumulated food intake during 130 days (day 21 to
150) in eight cages (three mice per cage) from both groups,
shows that AEA-treated mice ate 4.8 % more food than
control animals (2033 ± 32 g vs 1939 ± 28 g; P< 0.05).
Basal metabolic rate
The basal metabolic rate between both groups showed
no significant difference. Thus, oxygen consumption in
150 day-old control and AEA-treated mice was 1.6 ± 0.1
vs 1.7 ± 0.1 ml O2/g/h, respectively.
Western blot analysis of CB1R in epididymal fat
Figure 3 shows CB1R protein expression in epididymal
fat of 150 day-old control and AEA-treated mice. It was
observed that AEA-treated mice had 150 % higher ex-
pression than control mice (P< 0.05). Quantification of
CB1R bands were normalized against β-actin expression.
Glucose tolerance and insulin tolerance test
The glucose tolerance test performed in 150 day-old
mice, only revealed a significantly higher blood glucose
level in AEA-treated mice after 120 min (Figure 4a). In-
cremental AUC was 40 % higher in AEA-treated mice;
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however, this difference was not significant (Figure 4b).
To determine the effect of AEA treatment on insulin
sensitivity, an insulin tolerance test was performed. A
glucose-lowering effect of insulin was only observed in
control mice, which showed higher decrements in blood
glucose than AEA-treated mice (Figure 5a). AEA-treated
mice have a lower or negative decremental curve, indi-
cating a marked insulin resistance state in these animals
and as a result, a lower DAUC (Figure 5b).
Plasma glucose, lipids and hormonal levels
Overweight induced by AEA during lactation was asso-
ciated to changes in circulating metabolic markers com-
mon to metabolic syndrome. Thus, elevated levels of
blood glucose, plasma insulin, leptin and triglycerides
were observed. Due to higher epididymal fat accumula-
tion, which may be representative of a higher visceral fat
mass, AEA-treated mice showed increased NEFA plasma
levels (Table 1).
Figure 1 Body weight time course of AEA-treated mice and control, (a) during lactation and (b) at different ages from days 30 to 150.
(*P< 0.05/**P< 0.01 Mann–Whitney U test; mean ± SEM; n= 12/group).
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Discussion
In this study, we demonstrated that mice treated with an
excess of the endocannabinoid anandamide (AEA) dur-
ing lactation showed increased body weight, epididymal
fat accumulation, and a marked insulin resistance state
during adulthood. Therefore, the long term pathophysio-
logical condition programmed in such a critical period
of life may be a consequence of a transient hyperactiva-
tion of CB1R. Genetically and diet-induced obese animal
models have shown the presence of elevated levels of
endocannabinoids in central and peripheral tissues
[5,17,26]. Animal studies, together with clinical data in
humans, indicate that the impaired energy balance
observed in obesity is associated with an overactive
endocannabinoid system [16,27].
In the present study, AEA-treated mice ate 4.8 % more
food than control mice; however, this could only explain
close to half of the observed difference in body weight,
suggesting a lower energy expenditure of AEA-treated
mice. Basal metabolic rate was remained unchanged
Figure 2 Effect of AEA treatment during lactation on, (a) the total amount of epididymal fat, and (b) epididymal adiposity Index of
adult control and AEA-treated mice. (*P<0.05; Mann–Whitney U Test; mean ± SEM; n= 9/group).
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between control and AEA-treated mice, indicating a dif-
ference in energy expenditure, likely due to decreased
locomotor activity in AEA-treated adult mice. This find-
ing is supported by studies where rats chronically treated
with a CB1R antagonist (rimonabant), showed a transient
reduction in food intake but a long lasting reduction in
body weight, indicating a metabolic effect independent
of energy intake [28]. Moreover, in high fat-fed dogs that
normally develop abdominal obesity, chronic treatment
with rimonabant reduced the abdominal fat mass. Inter-
estingly, this fact was not related to the transient reduc-
tion in food intake and was not associated to any change
in basal metabolic rate [29].
Obesity is one of the major components of metabolic
syndrome and it is associated to elevated plasma levels
of NEFA and triglycerides (TG), which contribute to in-
sulin resistance in peripheral tissues, leading to the de-
velopment of Type 2 Diabetes [30,31]. In this study,
overweight and the higher accumulation of epididymal
fat in AEA-treated mice were followed by higher blood
glucose levels, elevated plasma levels of TG and a
marked insulin resistance state. Altogether, these results
characterize main markers of the metabolic syndrome.
Multiple pathways may lead to insulin resistance.
Enhanced availability of free fatty acids released from adi-
pose tissue as well as dietary fatty acids have been shown
to result in increased amounts of ectopic lipid stores in
non-adipose tissues, like skeletal muscle and liver [32].
These lipids, together with their metabolites, are able to
contribute to the development of insulin resistance [33].
Accumulation of an excess of lipids in the visceral fat
compartment is closely associated to adipocyte
hypertrophy in this tissue, which in turn leads to increased
lipolysis [33]. The excess of lipids is shunted to the liver
and skeletal muscle, which results in impaired insulin sig-
nalling within these tissues and consequent development
of insulin resistance [34]. In this sense, adult AEA-treated
mice during lactation should have an increased risk of ec-
topic lipid accumulation due to the elevated concentration
of circulating NEFA, which may be originated from the
higher content of visceral adipose tissue found in these ani-
mals. In addition, the higher accumulation of fat observed
in AEA-treated mice may lead to a chronic inflammatory
state which is associated to increased production of che-
mokines and pro-inflammatory cytokines such as tumor
necrosis factor alpha (TNF-α), leading to higher circulating
levels of these compounds. This condition may be contrib-
uting to the insulin resistance state observed in the present
study. In this sense, it has been reported that elevated
levels of TNF-α increase Ser307 phosphorylation of IRS-1
[35], therefore impairing the insulin signalling cascade. In
addition, lipid accumulation leads to increased lipid oxida-
tion, which results in enhanced oxidative stress, a condi-
tion known to contribute to a higher TNF-α secretion [36].
Recently, endocannabinoids have also been described as
a class of lipid-derived mediators that are able to contrib-
ute to the pathogenesis of insulin resistance. It has been
demonstrated that adipose tissue produce and is capable
of secreting AEA and 2-AG [37-39]. Furthermore, it is
likely that fat accumulation between muscle fibres, as a re-
sult of increased levels of plasmatic NEFA, could be ac-
companied by a higher local secretion of AEA. This
secretion allows paracrine functions, leading to impaired
insulin signalling. In this regard, it has been recently
demonstrated that stimulation of skeletal muscle CB1R
with AEA leads to impaired insulin-stimulated PKB/Akt
(Ser473) phosphorylation and reduced insulin-stimulated
glucose uptake [40], thus interfering with the signal trans-
duction mechanisms involved in insulin actions. In
addition, an AEA-independent mechanism leading to in-
sulin resistance may involve intramyocellular fat accumu-
lation through its consequent elevated availability of lipid
metabolites such as ceramides and diacylglycerols, which
affect insulin signalling [41].
Higher availability of AEA during lactation resulted in
long term increased levels of CB1R in adipose tissue,
which have been previously reported to be involved in
lipogenesis. It was demonstrated that CB1R activation
stimulates lipoprotein lipase (LPL) activity in cultured
adipocytes from C57BL/6 N mice [14]. This enzyme hy-
drolyses circulating TG from VLDL and chylomicrons,
facilitating the access of free fatty acids to adipocytes
where they are accumulated again as TG. Thus, a higher
LPL activity due to high levels of activated CB1R may
lead to adipocyte hypertrophy and a higher release of
free fatty acids to the circulation.
Figure 3 Relative levels of CB1R protein in epididymal fat of
adult AEA-treated and control mice. For densitometric
quantification purposes, β-actin was used as loading control. Results
are expressed as percentage relative to the expression in control
mice. (* P< 0.05; Mann–Whitney U test; mean ± SEM; n= 6/group).
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The two major endocannabinoids are originated from
arachidonic acid (AA) containing phospholipids. This
AA, together with linoleic acid, belongs to the n-6 family
of essential fatty acids. Since linoleic and AA acids
present in different tissues come from the diet, it is not
unexpected that high and low intake of polyunsaturated
fatty acids can influence levels of endocannabinoids. For
example, feeding suckling piglets with a milk formula
deficient in AA led to decreased levels of AEA and 2-
AG in brain compared to piglets consuming sow milk
[42]. In the same study, when mice were supplemented
with AA for 58 days, brain levels of AEA increased by
six-fold when compared to control animals [42]. Con-
versely, a higher intake of long-chain n-3 fatty acids can
eventually lead to decreased levels of both 2-AG and
AEA in brain and other tissues [43-45].
Although results in animal models may not be easily
extrapolated to human beings, it is possible that the higher
availability of n-6 fatty acids in Western diets could also
contribute to a higher availability of endocannabinoids
Figure 4 (a) Increase in blood glucose levels over basal glycemia during GTT performed in adult control and AEA-treated mice and, (b)
glucose incremental area under the curve (IAUC) for both groups. Basal glycemia was measured immediately before intraperitoneal glucose
administration (1.5 mg/g of body weight). (*P<0.05; Mann–Whitney U Test; mean ± SEM; n= 9/group).
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during fetal life and/or lactation, with important health con-
sequences in adulthood, such as greater propensity to
obesity.
Conclusion
The results of the present study demonstrated that body
fat accumulation, obesity/overweight, and its associated
metabolic disturbances such as insulin resistance and a
higher lipid profile, can be programmed at an early stage
of life as a result of the activation of CB1 receptors with
elevated doses of its agonist, the endocannabinoid AEA.
Thus, we can suggest that treatment with AEA during
lactation could be considered as a useful tool to study
Figure 5 (a) Decrease in blood glucose levels during ITT in adult control and AEA-treated mice and, (b) decremental glucose area
under the curve (DAUC) for both groups. Basal glycemia was measured immediately before intraperitoneal 0.75 U/Kg insulin administration.
(*P< 0.05/**P< 0.01 Mann–Whitney U test; mean ± SEM; n= 9/group).
Table 1 Plasma lipid profile, glucose, insulin and leptin
levels in 150 day-old, control and AEA-treated mice
during lactation
Plasma levels Control AEA-treated
TG (mg/dl) 114.4 ± 10.0 144.0 ± 6.0 *
Cholesterol (mg/dl) 100.6 ± 3.8 115.6 ± 3.1 *
NEFA (mg/dl) 2.7 ± 0.6 5.0 ± 0.7*
Glycemia (mg/dl) 114.7 ± 8.6 144.7 ± 7.0 **
Insulin (ng/ml) 1.6 ± 0.2 4.6 ± 0.6 **
Leptin (ng/ml) 5.8 ± 1.3 16.3 ± 2.5 **
Data represent the mean ± SEM of 10 mice from each group. *P< 0.05.
**P< 0.01
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some long-term physiopathological manifestations of the
metabolic syndrome.
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